Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

Avidity Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference


LA JOLLA, Calif., Dec. 22, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCstm), today announced that Sarah Boyce, President and Chief Executive Officer, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14th, 2021 at 12:40pm PST. The conference is being held in a virtual format.

A live webcast of the presentation will be available on the Company's website at www.aviditybiosciences.com in the Investor Resources section. A replay of the presentation will be archived on the Company's website for 30 days.

About Avidity Biosciences
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has research efforts focused on immune and other cell types.

Avidity is headquartered in La Jolla, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn.

Contacts:

Company:
Mike MacLean
(858) 401-7900
[email protected]          

Media and Investors:
Amy Conrad
Juniper Point
(858) 366-3243
[email protected]

 

SOURCE Avidity Biosciences, Inc.


These press releases may also interest you

at 11:53
Emmy-winning Cyberchase Expands Digital Presence to Engage Every Kid, Everywhere Ahead of Season 15 Premiere
Cyberchase, The WNET Group's multiple Emmy-winning math and environmental literacy series for kids ages 6-8, launches its 15th season with an unprecedented digital offering to meet young viewers where they are. An expansive slate of programming...

at 11:50
Testing Novel 3D Mapping Technology to Transform Space Exploration and Benefit Industries on Earth
When you go on a trip, you might reach for a map to help navigate your journey or pull up GPS on your phone. But what if the destination is on another planet, and there is no map? A new project sponsored by the International Space Station (ISS)...

at 11:50
Nullmax Showcases Comprehensive Autonomous Driving Solutions at Auto China 2024
Nullmax, an advanced autonomous driving company, is showcasing its innovative full-set of autonomous driving solutions at the 2024 Beijing International Automotive Exhibition (Auto China 2024), held at the China International Exhibition Center. The...

at 11:46
Alliant Credit Union Welcomes New Members to Board of Directors
Alliant Credit Union, a leader in digital banking and one of the largest credit unions in the nation, announces the appointment of four members to its board of directors. These additions to Alliant's board bring vast expertise spanning from leaders...

at 11:45
ISG to Evaluate Workday Ecosystem Providers
Information Services Group (ISG) , a leading global technology research and advisory firm, has launched a research study examining providers that help customers get the most out of the Workday cloud-based enterprise management platform. The study...

at 11:45
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
Vertex Pharmaceuticals today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following...

More news about Science and technology...


News published on and distributed by: